Isis Pharmaceuticals and Bayer HealthCare team up to prevent thrombosis

05/05/2015 - 2 minutes

Isis Pharmaceuticals and Bayer HealthCare will develop and commercialize ISIS-FXIRx for the prevention of thrombosis. The German Pharma will provide up to €139M to Isis, including an up-front payment of €89.6M.

Under the terms of the agreement, Isis is eligible to receive up to €139M in near-term payments, including an immediate €89.6M up-front payment and a €49.3M payment depending on the advancement of the program following a Phase II study on patients with compromised kidney function. Isis is also eligible to receive milestone payments as the drug advances towards the market and royalties of the commercialization.

After completion of ongoing activities at Isis, Bayer will assume all global clinical development as well as worldwide regulatory and commercialization responsibilities for ISIS-FXIRx. As part of the clinical development program, Bayer plans to evaluate the therapeutic profile of ISIS-FXIRx in patients for whom currently available anticoagulants may not be used, such as in patients with a high risk of bleeding due to multiple co-morbidities.

As Dr. Jöerg Möeller,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!